The institutional investor owned 1,191,263 shares of the company’s stock after buying an additional 658,763 shares during the period.
Advertisement
Midsize companies such as Teva have largely driven the breakneck pace of consolidation in the drug industry in recent years – part of a broader boom in mergers and acquisitions. Nuveen Asset Management LLC owned approximately 0.06% of Teva Pharmaceutical Industries worth $27,787,000 at the end of the most recent quarter.
Teva gapped open sharply higher Wednesday, but has pared its gains in early trade.
The stock price demonstrated downbeat change from its 50 day moving average of 51.80 and had been down from its 200 Day Moving Average of 55.92.
The average true range of Teva Pharmaceutical Industries Limited’s (TEVA) is recorded at 1.13 and the relative strength index of the stock stands 60.56. The company has a market cap of $47.95B. The company had revenue of $4.81 billion for the quarter, compared to analysts’ expectations of $4.78 billion.
By looking at Teva Pharmaceutical Industries Limited (TEVA) YTD (year to date) performance, the stock shows Negative value of -19.06%. They are also projecting the Low EPS estimate as $1.02 as compared to the Higher EPS estimate of $1.22.
Teva Pharmaceutical Industries (TEVA) announced Wednesday morning that it now expects to report second quarter adjusted EPS of $1.19 to $1.22, up from previous guidance of $1.16 to $1.20. Equities analysts predict that Teva Pharmaceutical Industries Ltd will post $5.25 earnings per share for the current fiscal year. The stock has a consensus analyst price target of $1.0000for twelve month. Maxim Group lowered their price target on Teva Pharmaceutical Industries from $74.00 to $70.00 and set a “buy” rating on the stock in a report on Monday, May 9th. BTIG Research reissued a “buy” rating and issued a $77.00 price target on shares of Teva Pharmaceutical Industries in a report on Thursday, April 7th.
Advertisement
According to ZACKS data, different Brokerage Firms rated the stock about their BUY, SELL or HOLD recommendations. Teva Pharmaceutical Industries has an average rating of “Buy” and an average target price of $71.00.
